Receive our newsletter – data, insights and analysis delivered to you
  1. Deals Analysis
March 21, 2019updated 22 Mar 2019 5:39am

US pharma industry sees a drop of 16.7% in deal activity in February 2019

The US pharma industry saw a drop of 16.7% in overall deal activity during February 2019, when compared with the last 12-month average, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the code below into your website to display the chart.

A total of 65 deals worth $28.06bn were announced in February 2019, compared to the 12-month average of 78 deals.

Venture financing was the leading category in the month in terms of volume with 46 deals which accounted for 70.8% of all deals.

In second place was M&A with 14 deals, followed by private equity with five transactions, respectively accounting for 21.5% and 7.7% of overall deal activity in the country’s pharma industry during the month.

Content from our partners
Extractables and leachables analysis in pharmaceutical quality control
How Hengst helped to keep Germany’s charity “star singers” shining
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

In terms of value of deals, M&A was the leading deal category in the US pharma industry with total deals worth $26.41bn, while venture financing and private equity deals totalled $1.04bn and $610.6m, respectively.

US pharma industry deals in February 2019: Top deals

The top five pharma industry deals accounted for 94.5% of the overall value during February 2019.

The combined value of the top five pharma industry deals stood at $26.51bn, against the overall value of $28.06bn recorded for the month. The top announced US pharma industry deal tracked by GlobalData in February 2019 was Danaher’s $21.4bn asset transaction with General Electric.

In second place was the $4.3bn acquisition of Spark Therapeutics by F. Hoffmann-La Roche and in third place was TPG Capital and Vida Ventures’ $300m private equity deal with Kadiant.

The $300m acquisition of Immune Design by Merck Sharp & Dohme and Clinigen Group’s asset transaction with Novartis for $210m held fourth and fifth positions, respectively.

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.

Verdict makes every effort to ensure the accuracy of its deals information. If you spot a mistake, or would like to notify us of a deal which should be included in this analysis, please email us at deals@globaldata.com

GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.

More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.

 

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU